Hiv Gp120 - Pharma

Relevant Publications

PKR Inhibitor C16 Regulates HIV-gp120 Induced Neuronal Injury and Cognitive Impairment in Vivo and in Vitro Models.

Issue Release: 2025

Reactive molecular dynamics simulations investigating ROS-mediated HIV damage from outer gp120 protein to internal capsid protein.

Issue Release: 2025

HIV-1 Structural Proteins or Cell-Signaling Factors? That Is the Question!

Issue Release: 2024

mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies.

Issue Release: 2024

Phospho-Chitooligosaccharides below 1 kDa Inhibit HIV-1 Entry In Vitro.

Issue Release: 2024

Nanocapsules Comprised of Purified Protein: Construction and Applications in Vaccine Research.

Issue Release: 2024

Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.

Issue Release: 2024

Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains.

Issue Release: 2024

Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses.

Issue Release: 2024

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Issue Release: 2024

Atherosclerosis and Cardiovascular Complications in People Living with HIV: A Focused Review.

Issue Release: 2024

HIV1 gp120 activates microglia via TLR2-NF-κB signaling to up-regulate inflammatory cytokine expression and induce neuropathic pain.

Issue Release: 2024

AI-based IsAb2.0 for antibody design.

Issue Release: 2024

Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.

Issue Release: 2024

Structural and Functional Dysregulation of the Brain Endothelium in HIV Infection and Substance Abuse.

Issue Release: 2024

Glycan-Modified Peptides for Dual Inhibition of Human Immunodeficiency Virus Entry into Dendritic Cells and T Cells.

Issue Release: 2024

Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1.

Issue Release: 2024

Interferon-β deficiency alters brain response to chronic HIV-1 envelope protein exposure in a transgenic model of NeuroHIV.

Issue Release: 2024

HIV and gp120-induced lipid droplets loss in hepatic stellate cells contribute to profibrotic profile.

Issue Release: 2024

Competitive assembly resolves the stoichiometry of essential proteins in infectious HIV-1 virions.

Issue Release: 2024

What is Medication Adherence?

Who Can Participate in Clinical Trials?

What is a New Drug Application (NDA)?

What are the Key Challenges?

What are the Phases of Clinical Trials?

Which Agencies are Involved?

What is Pharmaceutical Science?

Why are Collaborative Care Models Important in Pharma?

What is Regulatory Approval?

How Do Collaborative Care Models Work?

Partnered Content Networks

Relevant Topics